Wang Huaiyu, Wang Xuning, Jiang Suxin, Zhu Jingna, Liu Jie, Zhou Chuanhong, Zhu Yanjun, Han Yong
Thoracic Surgery Department, Air Force Medical Center, Chinese People's Liberation Army (PLA), Beijing, China.
Front Oncol. 2022 Aug 11;12:956372. doi: 10.3389/fonc.2022.956372. eCollection 2022.
A 50-year-old female patient presented with post-exercise dyspnea in September 2016, and was subsequently diagnosed with SCLC with multiple brain and spinal metastases. The first-line treatment was etoposide combined with cisplatin and synchronously performed radiotherapy for the brain and spinal cord metastases. She was treated with anlotinib after disease progression in December 2018 and continued to have clinical benefit for nearly 25 months. Unexpectedly, the patient can still benefit from further combination treatment with durvalumab after another disease progression in February 2021. Thus, it may be a potential option to use anlotinib along with immunotherapy after the anlotinib resistance in SCLC, but more clinical data are still needed to confirm it. Moreover, ctDNA dynamic monitoring was performed and reflected the outcome of the process of treatment.
一名50岁女性患者于2016年9月出现运动后呼吸困难，随后被诊断为小细胞肺癌伴多发脑和脊髓转移。一线治疗为依托泊苷联合顺铂，并同步对脑和脊髓转移灶进行放射治疗。2018年12月疾病进展后接受安罗替尼治疗，持续临床获益近25个月。出乎意料的是，该患者在2021年2月再次疾病进展后，仍可从与度伐利尤单抗的进一步联合治疗中获益。因此，小细胞肺癌出现安罗替尼耐药后联合免疫治疗可能是一种潜在选择，但仍需要更多临床数据来证实。此外，进行了循环肿瘤DNA动态监测，反映了治疗过程的结果。
